Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

2.64
+0.04501.74%
Volume:200.82K
Turnover:524.54K
Market Cap:195.88M
PE:-1.82
High:2.69
Open:2.63
Low:2.57
Close:2.59
52wk High:5.39
52wk Low:1.60
Shares:74.34M
Float Shares:58.98M
Volume Ratio:0.64
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4506
EPS(LYR):-1.2306
ROE:-37.26%
ROA:-17.24%
PB:0.81
PE(LYR):-2.14

Loading ...

Perspective Therapeutics Reports Promising [212Pb]VMT-α-NET Data in Neuroendocrine Tumor Trial

Reuters
·
Dec 04

Perspective Therapeutics (CATX) Receives a Buy from Roth MKM

TIPRANKS
·
Nov 28

Perspective Therapeutics (CATX) Receives a Buy from RBC Capital

TIPRANKS
·
Nov 26

Perspective Therapeutics Inc : Truist Securities Assumes Coverage With Buy Rating; Target Price $12

THOMSON REUTERS
·
Nov 24

Perspective Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Nov 22

Buy Rating Affirmed for Perspective Therapeutics Amid Promising Developments in VMT-α-NET Program

TIPRANKS
·
Nov 21

Perspective Therapeutics price target lowered to $7 from $18 at UBS

TIPRANKS
·
Nov 21

Perspective Therapeutics to Participate in Upcoming December Conferences

GlobeNewswire
·
Nov 20

Perspective Therapeutics Is Maintained at Buy by B. Riley Securities

Dow Jones
·
Nov 19

B. Riley Adjusts Price Target on Perspective Therapeutics to $11 From $12, Maintains Buy Rating

MT Newswires Live
·
Nov 18

Perspective Therapeutics Chief Accounting Officer Jonathan Robert Hunt Acquires Common Shares

Reuters
·
Nov 17

Director Robert F. Williamson III Acquires Common Shares of Perspective Therapeutics Inc

Reuters
·
Nov 14

RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
Nov 12

Buy Rating for Perspective Therapeutics: Promising Pipeline and Financial Stability

TIPRANKS
·
Nov 12

Buy Rating for Perspective Therapeutics: Promising Pb-212 Pipeline and Acquisition Potential

TIPRANKS
·
Nov 12

Wedbush Keeps Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
Nov 11

Perspective Therapeutics price target lowered to $13 from $14 at Oppenheimer

TIPRANKS
·
Nov 11

BTIG Sticks to Its Buy Rating for Perspective Therapeutics (CATX)

TIPRANKS
·
Nov 11

Perspective Therapeutics Reports Promising Q3 2025 Results

TIPRANKS
·
Nov 11

Perspective Therapeutics Q3 net loss widens to $26 mln

Reuters
·
Nov 11